budralazine has been researched along with benserazide in 1 studies
*Benserazide: An inhibitor of DOPA DECARBOXYLASE that does not enter the central nervous system. It is often given with LEVODOPA in the treatment of parkinsonism to prevent the conversion of levodopa to dopamine in the periphery, thereby increasing the amount that reaches the central nervous system and reducing the required dose. It has no antiparkinson actions when given alone. [MeSH]
*Benserazide: An inhibitor of DOPA DECARBOXYLASE that does not enter the central nervous system. It is often given with LEVODOPA in the treatment of parkinsonism to prevent the conversion of levodopa to dopamine in the periphery, thereby increasing the amount that reaches the central nervous system and reducing the required dose. It has no antiparkinson actions when given alone. [MeSH]
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kawai, K; Kitamura, J; Mori, H; Sugie, S | 1 |
1 other study(ies) available for budralazine and benserazide
| Article | Year |
|---|---|
Genetic toxicity of several antihypertensive drugs possessing a hydrazine group.
Topics: Animals; Antihypertensive Agents; Benserazide; Carbidopa; Hydralazine; Hydrazines; Male; Mutagens; Rats; Rats, Inbred ACI | 1985 |